Evidence map›Paper›PMID 28711998›Full record

ArticleJournal of neurology2017

Medical history of chemotherapy or immunosuppressive drug treatment and risk of amyotrophic lateral sclerosis (ALS).

Thomas Kuczmarski, Elijah W Stommel, Kristen Riley, Rup Tandan, Vinay Chaudhry, Lora Clawson, Tracie A Caller, Patricia L Henegan, Dominic N Facciponte, Walter G Bradley and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Thomas KuczmarskiDepartment of Neurology, Dartmouth-Hitchcock Medical Center, 7936 Rubin Building, One Medical Center Drive, Lebanon, NH, 03756, USA.
Elijah W StommelDepartment of Neurology, Dartmouth-Hitchcock Medical Center, 7936 Rubin Building, One Medical Center Drive, Lebanon, NH, 03756, USA.
Kristen RileyDepartment of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Rup TandanDepartment of Neurological Sciences, University of Vermont Medical Center, Burlington, VT, USA.
Vinay ChaudhryDepartment of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Lora ClawsonDepartment of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Tracie A CallerCheyenne Regional Medical Center, Medical Specialty Clinic, Cheyenne, WY, USA.
Patricia L HeneganDepartment of Neurology, Dartmouth-Hitchcock Medical Center, 7936 Rubin Building, One Medical Center Drive, Lebanon, NH, 03756, USA.
Dominic N FacciponteDepartment of Neurology, Dartmouth-Hitchcock Medical Center, 7936 Rubin Building, One Medical Center Drive, Lebanon, NH, 03756, USA.
Walter G BradleyDepartment of Neurology, Miller School of Medicine, University of Miami, Miami, FL, USA.
Angeline S AndrewDepartment of Neurology, Dartmouth-Hitchcock Medical Center, 7936 Rubin Building, One Medical Center Drive, Lebanon, NH, 03756, USA. Angeline.Andrew@dartmouth.edu.ORCID http://orcid.org/0000-0002-3731-5300
Dartmouth–Hitchcock Medical Center · USJohns Hopkins University · USCheyenne Regional Medical Center · USUniversity of Miami · USUniversity of Vermont Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A recent population-based analysis demonstrated lower risk of the lethal degenerative neuromuscular disease, amyotrophic lateral sclerosis (ALS) associated with history of the use of 'antineoplastic agents' and 'immunosuppressants'. To see if this finding was generalizable to other ALS cohorts, we examined associations between use of these agents and ALS risk in an independent case-control study of n = 414 ALS patients and n = 361 controls in an Eastern US population. Controls were sampled from the general population and among non-neurodegenerative disease patients. A history of chemotherapy treatment was significantly associated with a decreased ALS risk (OR 0.46, 95% CI 0.22-0.89, P = 0.026). We did not observe an association between risk of ALS and immunosuppressant therapy use (OR 0.78, 95% CI 0.50-1.02, P = 0.23). Analyses were adjusted for age, gender, and smoking. Our results support the prior report for chemotherapy treatment and lead to further discussion of the underlying mechanism.

Indexed as

Antineoplastic AgentsImmunosuppressive AgentsAge FactorsAmyotrophic Lateral SclerosisCase-Control StudiesFemaleHumansMaleMiddle AgedOdds RatioRisk FactorsSex FactorsSmokingUnited StatesAntineoplastic AgentsImmunosuppressive AgentsAmyotrophic lateral sclerosisCase–controlChemotherapyImmunosuppressantNeurodegenerative

Identifiers

PMID28711998
OpenAlexW2736028645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.